Nice try. You just undermined your argument that AVXL needs cash if it is going to merge with a entry biotech. If we have cash enough to bail out another biotech we have enough to run trials ourselves, and thus should get going. I think we have enough cash to run 2 trials at $40m apiece while keeping the doors open, especially with new lower payroll costs now that the bureaucrat parasite hires are gone.
Market Data 
Markets 
